eISSN: 1897-4317
ISSN: 1895-5770
Gastroenterology Review/Przegląd Gastroenterologiczny
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

without publication fees
2/2024
vol. 19
 
Share:
Send email
Share:
abstract:
Original paper

Vonoprazan a novel potassium competitive acid blocker; another leap forward

Maha Elsabaawy
1
,
Ahmed Shaban
1
,
Ahmed Ezz Al-Arab
2
,
Osama Elbahr
1
,
Ahmed Edrees
1
,
Sameh Afify
1

  1. Depatment of Hepatology and Gastroenterology, National Liver Institute, Menoufia University, Shebeen El‑Koum, Menoufia, Egypt
  2. Depatment of internal Medicine, Faculty of Medicine, Menoufia University, Shebeen El‑Koum, Menoufia, Egypt
Gastroenterology Rev 2024; 19 (2): 135–142
DOI: https://doi.org/10.5114/pg.2024.139426
Online publish date: 2024/05/08
View full text Get citation
 
PlumX metrics:
Introduction
The eradication rate of Helicobacter pylori (H. pylori) has decreased due to antibiotics resistance and inadequate acid suppression. Vonoprazan is a novel potassium-competitive acid blocker (P-CAB), which has a rapid and sustained acid inhibitory effect and may be more effective than conventional proton pump inhibitors (PPIs) in H. pylori eradication.

Aim
to study the efficacy and safety of vonoprazan as a component of first-line H. pylori eradication treatment compared with conventional PPI-based therapy.

Material and methods
This randomised (one to one) non-blinded study was conducted on 400 consecutive proven H. pylori infected patients, of whom 200 received vonoprazan-based triple therapy, while 200 patients received PPI-based triple therapy for 14 days. The study outcomes were evaluated as eradication rate and adverse events in both patient groups.

Results
The eradication rate was 86% in the vonoprazan group and 74.5% in the PPI group. The vonoprazan eradication rate was significantly higher than that of PPIs (p = 0.004). There was no significant difference regarding adverse events between both patient groups.

Conclusions
Vonoprazan-based therapy was more effective than PPI-based therapy as a first-line H. pylori eradication treatment. Vonoprazan was generally safe and well tolerated.

keywords:

Helicobacter pylori eradication, potassium-competitive acid blocker (P-CAB), proton pump inhibitors (PPIs), vonoprazan
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.